Biogen

Biogen, founded in 1978, is a prominent U.S.-based biotechnology firm specializing in the discovery, development, and commercialization of therapies for serious neurological and neurodegenerative diseases. The company maintains a robust portfolio targeting conditions such as multiple sclerosis, spinal muscular atrophy, and various rare neurological disorders. By leveraging advanced research in neuroscience, biologics, and gene-based therapies, Biogen continues to drive innovation within the global pharmaceutical and healthcare sectors.

Operating with a workforce of 5,000-10,000 employees, the company manages a complex infrastructure across 59 locations worldwide. Learn about Biogen's global headquarters for detailed information regarding their operational footprint in Cambridge, Massachusetts. This extensive network supports their mission to deliver breakthrough medical solutions while maintaining high standards in clinical research and manufacturing. The firm’s strategic focus remains on addressing significant unmet medical needs through rigorous scientific inquiry and patient-centric service models.

Biogen competes with major industry players such as Regeneron, Gilead Sciences, and Vertex, positioning itself as a leader in the biopharmaceutical landscape. Meet Biogen's team to gain insights into the leadership and organizational structure driving their strategic initiatives. With a ticker symbol of NASDAQ: BIIB, the company remains a key entity in the biotechnology market, consistently investing in novel drug development and patient advocacy programs. Their commitment to human health and scientific excellence underscores their long-term growth strategy in an increasingly competitive global market.